We evaluated the outcome of 227 patients with acute myeloid leukemia during three decades (period 1 - 1980's, N = 89; period 2 - 1990's, N = 73; period 3 - 2000's, N = 65) at a single institution. Major differences between the three groups included a higher median age, rates of multilineage dysplasia and co-morbidities, and a lower rate of clinical manifestations of advanced leukemia in recent years. The proportion of patients who received induction remission chemotherapy was 66, 75, and 85% for periods 1, 2, and 3, respectively (P = 0.04). The median survival was 40, 77, and 112 days, and the 5-year overall survival was 7, 13, and 22%, respectively (P = 0.01). The median disease-free survival was 266, 278, and 386 days (P = 0.049). Survival expectation for patients with acute myeloid leukemia has substantially improved during this 30-year period, due to a combination of lower tumor burden and a more efficient use of chemotherapy and supportive care.
CITATION STYLE
Souto Filho, J. T., Portugal, R. D., Loureiro, M., Pulcheri, W., & Nucci, M. (2011). Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades. Brazilian Journal of Medical and Biological Research, 44(7), 660–665. https://doi.org/10.1590/s0100-879x2011007500058
Mendeley helps you to discover research relevant for your work.